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Key Points
•Children with PCNSL
and no immunodefi-
ciency have a good
outcome when treated
by a histological
subtype–driven and
radiation-free protocol.
•New treatment guide-
lines are needed for
PCNSL in children and
adolescents with an
underlying
immunodeficiency.
Introduction
Primary central nervous system lymphoma (PCNSL) is a rare subtype of non-Hodgkin lymphoma (NHL) in
childhood and adolescence, with an increased risk among patients with immunodeficiency.1-5 Given the
rarity and lack of any prospective trials, reliable data on PCNSL are lacking, with most data coming from
case reports or small series. Thus, 2 of the largest childhood NHL consortia, the European Intergroup for
Childhood Non-Hodgkin Lymphoma (EICNHL) and the international Berlin-Frankfurt-Mu¨nster (i-BFM)
Group, as well as selected North American centers, designed a retrospective multinational study on
pediatric PCNSL. Here, we present data from the largest series of pediatric patients with PCNSL
reported to date.
Methods
We conducted a retrospective survey of children and adolescents up to 19 years of age who were
diagnosed with PCNSL between 1991 and 2019. Patient data were retrieved from 21 EICNHL and/or
i-BFM Group members or selected North American institutions. The survey included questions about
demographics, disease, treatment, outcome, and late effects. PCNSL was defined by intracerebral/
intraspinal mass(es) and/or cranial nerve palsies not caused by an extradural tumor and/or tumor cells
in the cerebrospinal fluid and/or involvement of the eye(s). Although the 2016 World Health Organization
Classification now recognizes diffuse large B-cell lymphoma (DLBCL) of the central nervous system (CNS)
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as a distinct lymphoma, PCNSL is an accepted clinical term that is
independent from the histopathology.1,2,5-7 For this reason, we included
all histologic subtypes. For patients enrolled in national trials/registries,
data collection was approved by the respective ethics committees.8-23
In nontrial/nonregistry patients, the retrospective data collection
was performed with local Institutional Review Board approval.
Seventy-five patients with PCNSL were identified. Diagnosis of the
NHL subtype was based on contemporaneous pathological criteria.6,24-27
Event-free survival (EFS) was calculated from date of diagnosis to date of
first event. Events considered were relapse, progression, and death.
Overall survival (OS) was defined as the time from diagnosis to death
from any cause or date of last follow-up. EFS and OS curves were
estimated according to the Kaplan-Meier method. The Cox proportional-
hazard model was used for multivariate analyses of EFS and OS.
Table 1. Initial characteristics and therapy of the 75 PCNSL study
patients
Variable Patients
Patients, n 75
Sex
Female 29 (39)
Male 46 (61)
Age, y
Median (range) 12.5 (1.25-18.87)
,10 26 (35)
$10 to ,15 31 (41)
$15 18 (24)
Preexisting disorder
Yes 14 (19)
No 56 (75)
Unknown 5 (6)
Lansky score
,40% 14 (19)
$40-79% 27 (36)
$80% 19 (25)
Unknown/not applicable 15 (20)
B symptoms
Yes 9 (12)
No 59 (79)
Unknown 7 (9)
Cranial nerve palsies
Yes 33 (44)
No 39 (52)
Unknown 3 (4)
Histopathologic subtype
DLBCL 37 (49)
Burkitt lymphoma 9 (12)
Mature B-NHL NOS 5 (7)
ALCL 17 (23)
Other NHL 7 (9)
BCP LBL, n 4
EN MZL, n 1
PTCL, n 2
Localization
Intracranial 70 (93)
Intraspinal only 2 (3)
Leptomeningeal only 3 (4)
No. of lesions
1 36 (48)
$2 32 (43)
Unknown/not applicable 7 (9)
Initial LDH level, U/L
,500 53 (71)
$500 10 (13)
Unknown 12 (16)
Table 1. (continued)
Variable Patients
Initial therapy
Chemo only 31 (41)
Chemo and rituximab 15 (20)
Chemo and RT 24 (32)
Chemo and rituximab and RT 2 (3)
Other 3 (4)
Therapy
Pediatric NHL-type* 57 (76)
Adult NHL-type† 1 (1)
Miscellaneous‡ 17 (23)
Chemotherapeutic drugs, n§
High-dose methotrexate 68
High-dose cytarabine 55
Anthracyclines 59
Alkylating agents 64
Intrathecal therapies 69
RT
Yes 26 (35)
No 49 (65)
Stem cell therapy in CR1
Autologous 3 (4)
Allogeneic 1 (1)
Rituximab in mature B-NHL 17 (32)
Unless otherwise noted, data are shown as n (%).
BCP, B-cell precursor; Chemo, chemotherapy; CR1, first complete remission; EN MZL,
extranodal marginal zone lymphoma; LDH, lactate dehydrogenase; NOS, not otherwise
specified; RT, radiotherapy.
*NHL Berlin-Frankfurt-Mu¨nster therapy, n 5 30; Lymphomes Malins B therapy, n 5 14;
Inter–B-NHL therapy, n 5 5; Associazione Italiana Ematologia Oncologia Pediatrica linfoma
non-Hodgkin (AIEOP LNH) therapy, n 5 2; EICNHL therapy, n 5 2; Sociedade de
Hematologia e Oncologia Pediatrica LNH therapy, n 5 1; Japanese Pediatric Leukemia/
Lymphoma Study Group B-NHL therapy, n 5 2;, Children’s Oncology Group AALL1131
trial, n 5 1, including 17 of the 26 (65%) patients with RT.
†Cancer and Leukemia Group B 50202 trial, n 5 1.
‡Including 9 of the 26 (35%) patients with RT.
§High-dose-methotrexate (n 5 68): ,5 g/m2, n 5 5; 5 g/m2, n 5 38; 8 g/m2, n 5 25.
High-dose-cytarabine (n 5 55): #6 g/m2, n 5 13; 8 g/m2, n 5 1; 12 to 12.5 g/m2, n 5 41.
Anthracyclines (n 5 59) with doxorubicin in 57 patients and a median cumulative dose of
100 mg/m2 (range: 25-240 mg/m2).
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Results and discussion
The study cohort is shown in Tables 1-3 and supplemental
Tables 1-3. The male/female ratio was 1.7:1, and median age
was 12.5 years. Three histopathological subgroups were identi-
fied: (1) mature B-cell NHL (B-NHL; n 5 51; 68%, including
DLBCL [n 5 37], Burkitt lymphoma [n 5 9], and B-NHL, not
otherwise specified [n 5 5]), (2) anaplastic large cell lymphoma
(ALCL; n 5 17; 23%), and (3) other NHL (n 5 7; 9%, including
B-cell precursor lymphoblastic lymphoma [LBL; n5 4], peripheral
T-cell lymphoma [PTCL; n 5 2], and extranodal marginal zone
lymphoma [n 5 1]). Fourteen patients (19%) had preexisting
disorders, including immunodeficiency (n 5 11), hematologic
malignancy (n5 2), and factor VII deficiency (n5 1). Epstein-Barr
virus (EBV) status was documented in 47 patients, among whom
9 (19%) were EBV1.
Median time to diagnosis was 6.4 weeks, with 31 patients (41%)
receiving a diagnosis within 4 weeks of symptom onset. Thirty-three
patients (44%) presented with cranial nerve palsies. Seventy patients
(93%) had solid intracranial masses, 2 patients (3%) had intraspinal
mass(es) only, and 3 patients (4%) had leptomeningeal disease with
involvement of the cerebrospinal fluid only. The Lansky score was available
in 60 patients: 19 had a score$ 80%, and 14 had a score, 40%.28
Fifty-eight patients (77%) were treated according to NHL-subtype–
directed protocols (pediatric type, n 5 57; adult type, n 5 1;
B-NHL–block therapy: B-NHLs, n 5 38, ALCL, n 5 14; leukemia-
type therapy: LBL, n 5 4, PTCL, n 5 2), and 17 patients (23%)
received miscellaneous therapies.8-23 Thirty-one patients (41%)
were treated with chemotherapy only, 15 (20%) were treated with
chemotherapy 1 rituximab, 24 (32%) were treated with chemother-
apy 1 radiotherapy, and 2 (3%) were treated with chemotherapy 1
rituximab 1 radiotherapy. One patient underwent observation alone
after total resection, 1 received no therapy for 3 months for logistic
reasons, and 1 patients remained without therapy.
The chemotherapeutic cycles included high-dose methotrexate in
68 patients (91%), high-dose cytarabine in 55 patients (73%), and
anthracyclines in 59 patients (79%). Alkylating agents were used
in 64 patients (85%), with cyclophosphamide used in 61 patients.
Intrathecal therapies were used in 69 patients (92%) including
triple therapies in 56 patients. Twenty-six patients underwent
irradiation (35%; whole brain, n 5 22) with a dose range of
18 to 45 Gy (ALCL, n 5 13; DLBCL, n 5 9; other NHL, n 5 4).
Table 2. Disease outcome and long-term side effects of the 75 PCNSL
study patients
Variable Patients
Treatment failure
Median (range) time to, y 0.77 (0.27-6.78)
Relapse* 12 (16)
Progression 2 (3)
Localization of failure, n
CNS only 8
CNS and other 2
Outside CNS only 2
Unknown 1
Multiple sites n.f.s. 1
Death 12 (16)
Relapse/progression, n 6
Without any therapy, n 1
Therapy-related toxicity, n 4
Unknown, n 1
Second malignancy, n 0
Continuous CR 58 (75)
Follow-up
Median (range), y 5.22 (0.19-25.29)
In CR1 53 (91)
In CR2 5 (9)
CR not yet achieved at LFU, n 5
Long-term side effects
Neurological 22 (29)
Endocrine 3 (4)
Cardiac 0 (0)
Other 7 (9)
Osteonecrosis, n 5
Psychosocial, n 1
GVHD, CMV-associated retinitis, n 1
Unless otherwise noted, data are shown as n (%).
CMV, cytomegalovirus; CR, complete remission; CR1, first complete remission; CR2,
second complete remission; GVHD, graft-versus-host disease; LFU, last follow-up; n.f.s.,
not further specified.
*ALCL, n 5 6; DLBCL, n 5 5; Burkitt lymphoma, n 5 1; extranodal marginal zone
lymphoma, n 5 1; LBL, n 5 1.
Table 3. Characteristics of the 14 PCNSL patients with preexisting
disorders
Type of preexisting
disorder
Patients,
n Histology Event
Immunodeficiency
HIV infection 2 Burkitt lymphoma/
DLBCL
No/dead: TRM
(sepsis)
St. p. heart transplantation 1 DLBCL Dead: TRM (graft
failure)
St. p. kidney
transplantation
1 DLBCL No
St. p. liver transplantation 1 DLBCL No
SLE 1 DLBCL Dead (cause
unknown)
CLIPPERS 1 DLBCL No
Colitis ulcerosa 1 DLBCL Dead: TRM (details
NA)
PID n.f.s. 2 DLBCL/DLBCL No/dead of disease
CVID 1 ALCL Dead: TRM
(pneumonia)
Other disorders
B-cell precursor LBL 1 DLBCL No
JMML 1 DLBCL Relapse
Factor VIII deficiency 1 ALCL No
CLIPPERS, chronic lymphocytic inflammation with pontine perivascular enhancement re-
sponsive to steroids; CVID, common variable immunodeficiency; JMML, juvenile myelomonocytic
leukemia; NA, not available; PID n.f.s., primary immunodeficiency not further specified; SLE,
systemic lupus erythematosus; St. p., status post; TRM, treatment-related mortality.
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Four patients (5%) completed therapy with a stem cell trans-
plantation (autologous, n 5 3; allogeneic, n 5 1). After a median
time of 5.22 years, 5-year EFS and OS were 74% 6 5% and
85% 6 4%, respectively (Figure 1A-B). Of the 75 patients, 14
(19%) had primary treatment failure (relapse; n 5 12; pro-
gression, n 5 2) after a median time of 0.77 years, including only
1 patient with a preexisting disorder. Twelve patients (16%) died,
including 6 after relapse, 1 from PCNSL without any therapy, 4 from
treatment-related toxicity as a first event, and 1 from unknown causes.
Of the latter 6 patients, all had preexisting disorders.
Univariate analysis showed that preexisting disorders (EFS, 77%6 6%
vs 53%6 14%,P5 .027; OS, 89%6 5% vs 62%6 14%,P5 .001)
and number of lesions (1 vs $2 lesions: EFS, 89% 6 5% vs
66% 6 9%, P 5 .085; OS, 97% 6 3% vs 76% 6 8%, P 5 .043)
were associated with inferior outcome (Figure 1C-D). In contrast,
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Figure 1. EFS and OS rates of the 75 PCNSL patients
according to risk factors. EFS (A) and OS (B) of the 75
PCNSL patients. (C) EFS of the 56 PCNSL patients
without a preexisting disorder vs 14 PCNSL patients with
a preexisting disorder. (D) EFS of the 36 PCNSL patients
with 1 lesion vs 32 PCNSL patients with $2 lesions. (E)
EFS of the 68 PCNSL patients who received therapies that
included high-dose methotrexate vs 6 PCNSL patients who
did not receive high-dose methotrexate. (F) EFS of the 55
PCNSL patients who received therapies with high-dose
cytarabine vs 19 PCNSL patients who did not receive
high-dose cytarabine.
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high-dose methotrexate (P5 .0002), high-dose cytarabine (P5 .012),
and alkylating agents (P 5 .033) were associated with improved
EFS (Figure 1E-F). Other factors, including age, sex, Lansky score,
B symptoms, histopathology, type of therapy, rituximab in B-NHLs,
or radiotherapy, had no significant impact on EFS or OS (supplemental
Table 4). In multivariate analysis, high-dose methotrexate remained
significant for EFS, and preexisting disorders remained significant
for OS. Analysis of 60 patients without preexisting disorders showed
an EFS of 83% 6 5% for pediatric NHL therapy vs 57% 6 19% for
miscellaneous therapy (P 5 .044; supplemental Figure 1), whereas,
among 14 patients with a preexisting disorder, 5 of 6 patients with
NHL therapy had an event but only 2 of 8 patients with miscellaneous
therapy had an event.
Long-term sequelae were primarily neurological (n 5 22, 29%;
including 8/26 with radiotherapy) and rarely affected endocrine organs
(n 5 3, 4%), heart (n 5 0), or other organs/systems (n 5 7, 9%).
This report on 75 patients with PCNSL represents the largest series
of PCNSL in childhood and adolescence reported to date.1-3,29-31
Our results show that PCNSL is associated with male sex, age
$ 10 years, solid intracerebral disease, and immunodeficiency.
Among adults with PCNSL, the majority of cases are DLBCL
(90%).7 In our cohort, DLBCL was the most common histology, but
it was observed in only 49% of cases, suggesting that histopathol-
ogy of PCNSL in pediatrics might be distinct.
EFS of 74% 6 5% for the entire cohort is comparable to that of
children with CNS1 systemic NHL and similar to the 2-year
progression-free survival of 61% that was reported by the Interna-
tional PCNSL Collaborative Group in 29 2- to 21-year-old PCNSL
patients.11-13,15,16,23,29 Our favorable outcome has been achieved
by histological subtype–directed polychemotherapy in most patients,
suggesting that pediatric PCNSL can be successfully managed
by protocols designed for children with CNS1 systemic NHL, usu-
ally including high-dose methotrexate and high-dose cytarabine,
steroids, and no irradiation (except for ALCL).11-13,15,16,23,29 Our
evaluation of prognostic factors found preexisting disorders to be
associated with inferior EFS and OS. In contrast, usage of high-dose
methotrexate, high-dose cytarabine, and alkylators, which are
fundamental drugs of all pediatric NHL-subtype protocols/trials,
were associated with improved prognosis.11-13,15,16,21,23,29
Our study has limitations, including its retrospective nature, with
potential for reporting bias. For subanalyses, patient numbers were
small and included different histologic entities. Nevertheless, given
the rarity of this entity, these data are likely to be the best available
to determine important factors in the treatment and outcome of
pediatric PCNSL. This international collaboration allowed us to
conclude that treatment recommendations are especially needed
for PCNSL patients with immunodeficiencies, who are at risk for
treatment-related toxicity/mortality, whereas immunocompetent
PCNSL patients receiving pediatric histological subtype–directed
polychemotherapy and no irradiation do well.
Acknowledgments
The authors thank all participating institutions andphysicians for their
support of the study. This EICNHL and i-BFM article was written on
behalf of the Berlin-Frankfurt-Mu¨nster (BFM) Study Group (Austria,
Germany, Switzerland, Czech Republic), Associazione Italiana
Ematologia Oncologia Pediatrica, Socie´te´ Française de Lutte
contre les Cancers et Leuce´mies de l’Enfant, United Kingdom
Children’s Cancer and Leukemia Study Group, Belgian Society of
Pediatric Hematology and Oncology, Dutch Childhood Oncology
Group, Slovenian Society of Hematology and Oncology, Serbian
Society of Hematology and Oncology, Polish Society of Pediat-
ric Oncology and Hematology, Japanese Pediatric Leukemia/
Lymphoma Study Group, Hong Kong Pediatric Hematology and
Oncology Study Group, Spanish Society of Pediatric Hematology
and Oncology, Hellenic Society of Pediatric Hematology and
Oncology, and 5 single institutions from Armenia (Yerevan), Australia
(Perth), Canada (Toronto), Belarus (Minsk), and Russia (Moscow)
and 2 centers from the United States (Phoenix, Washington, DC).
This work was supported by Cancer Research United Kingdom,
the Deutsche Kinderkrebsstiftung (DKS 2014.11A/B, DKS
2016.24A/B, BFM Germany) (B.B. and W.W.), the St. Anna
Kinderkrebsforschung (BFM Austria) (A.A.), Project No. LQ1605
of the National Program of Sustainability II and Project Nos.
00064203 and 65269705 of the Czech Ministry of Health (Czech
Republic) (E.K.), and the Ministry of Health, Labour andWelfare of
Japan (Japanese Pediatric Leukemia/LymphomaStudyGroup) (T.O.).
L.G.-R. is supported by National Institutes of Health, National Cancer
Institute grant K08 CA219473.
Authorship
Contribution: A.A., O.A., and L.G.-R. designed and planned the study
and wrote the manuscript; A.A., S. Bansil, S.T., and L.R. pooled data,
checked data, and performed statistical analyses; S. Bomken, B.B.,
F.C., A.K.S.C., H.D., A.F., M.H., J.J., E.K., R.S.K., J. Lazic, J. Loeffen,
N.M., T.O.,M.P., A.P., C.R.,G.T., A.U., J.V.-A.,W.W.,G.W., A.A., O.A.,
and L.G.-R. were principal investigators or coinvestigators in their
study groups and institutions, coordinated the national trials in their
countries, provided study materials, and recruited patients; and all
authors read and approved the final version of the manuscript.
Conflict-of-interest disclosure: L.G.-R. has acted as a consultant
for Janssen, ADC Therapeutics, and Celgene. The remaining
authors declare no competing financial interests.
ORCID profiles: B.B., 0000-0002-1151-829X; A.K.S.C., 0000-
0002-1089-5325; A.F., 0000-0002-1559-8223; R.S.K., 0000-
0003-1836-4075; T.O., 0000-0001-5536-6788; G.W., 0000-
0003-4374-6083.
Correspondence: Andishe Attarbaschi, St. Anna Children’s
Hospital, Kinderspitalgasse 6, 1090 Vienna, Austria; e-mail:
andishe.attarbaschi@stanna.at.
References
1. Abla O, Sandlund JT, Sung L, et al. A case series of pediatric primary central nervous system lymphoma: favorable outcome without cranial irradiation.
Pediatr Blood Cancer. 2006;47(7):880-885.
2. Giulino-Roth L, Abla O, Batchelor TT. Management of primary central nervous system lymphoma in children. Hematology Am Soc Hematol Educ
Program. 2016;2016:386-389.
23 DECEMBER 2019 x VOLUME 3, NUMBER 24 PRIMARY CNS LYMPHOMA IN CHILDREN AND ADOLESCENTS 4295
D
ow
nloaded from
 https://ashpublications.org/bloodadvances/article-pdf/3/24/4291/1549805/advancesadv2019001062.pdf by guest on 23 D
ecem
ber 2019
3. Thorer H, Zimmermann M, Makarova O, et al. Primary central nervous system lymphoma in children and adolescents: low relapse rate after
treatment according to Non-Hodgkin-Lymphoma Berlin-Frankfurt-Mu¨nster protocols for systemic lymphoma. Haematologica. 2014;99(11):
e238-e241.
4. Attarbaschi A, Carraro E, Abla O, et al; European Intergroup for Childhood Non-Hodgkin Lymphoma (EICNHL) and the International Berlin-Frankfur
t-Mu¨nster (i-BFM) Study Group. Non-Hodgkin lymphoma and pre-existing conditions: spectrum, clinical characteristics and outcome in 213 children and
adolescents. Haematologica. 2016;101(12):1581-1591.
5. Batchelor T, Loeffler JS. Primary CNS lymphoma. J Clin Oncol. 2006;24(8):1281-1288.
6. Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of theWorld Health Organization classification of lymphoid neoplasms.Blood. 2016;127(20):
2375-2390.
7. Grommes C, DeAngelis LM. Primary CNS Lymphoma. J Clin Oncol. 2017;35(21):2410-2418.
8. Brugie`res L, Le Deley MC, Rosolen A, et al. Impact of the methotrexate administration dose on the need for intrathecal treatment in children and
adolescents with anaplastic large-cell lymphoma: results of a randomized trial of the EICNHL Group. J Clin Oncol. 2009;27(6):897-903.
9. Le Deley MC, Rosolen A, Williams DM, et al. Vinblastine in children and adolescents with high-risk anaplastic large-cell lymphoma: results of the
randomized ALCL99-vinblastine trial. J Clin Oncol. 2010;28(25):3987-3993.
10. Seidemann K, Tiemann M, Schrappe M, et al. Short-pulse B-non-Hodgkin lymphoma-type chemotherapy is efficacious treatment for pediatric anaplastic
large cell lymphoma: a report of the Berlin-Frankfurt-Mu¨nster Group Trial NHL-BFM 90. Blood. 2001;97(12):3699-3706.
11. Williams D, Mori T, Reiter A, et al; European Intergroup for Childhood Non-Hodgkin Lymphoma, the Japanese Pediatric Leukemia/Lymphoma Study
Group. Central nervous system involvement in anaplastic large cell lymphoma in childhood: results from a multicentre European and Japanese study.
Pediatr Blood Cancer. 2013;60(10):E118-E121.
12. Burkhardt B,WoessmannW, Zimmermann M, et al. Impact of cranial radiotherapy on central nervous system prophylaxis in children and adolescents with
central nervous system-negative stage III or IV lymphoblastic lymphoma. J Clin Oncol. 2006;24(3):491-499.
13. Cairo MS, Gerrard M, Sposto R, et al; FAB LMB96 International Study Committee. Results of a randomized international study of high-risk
central nervous system B non-Hodgkin lymphoma and B acute lymphoblastic leukemia in children and adolescents. Blood. 2007;
109(7):2736-2743.
14. Forns M, Javier G, Estella J, et al; en representacio´n del grupo SHOP de las Sociedades Españolas de Hematologı´a (SEHP) y Oncologı´a Pedia´tricas
(SEOP). [Results of the SHOP LNHB98 (LMB89) trial in pediatric patients with B-cell non-Hodgkin’s lymphoma]. Med Clin (Barc). 2007;128(17):
641-646.
15. Frazer JK, Li KJ, Galardy PJ, et al. Excellent outcomes in children and adolescents with CNS1 Burkitt lymphoma or other mature B-NHL using only
intrathecal and systemic chemoimmunotherapy: results from FAB/LMB96 and COG ANHL01P1. Br J Haematol. 2019;185(2):374-377.
16. Landmann E, Burkhardt B, Zimmermann M, et al. Results and conclusions of the European Intergroup EURO-LB02 trial in children and adolescents with
lymphoblastic lymphoma. Haematologica. 2017;102(12):2086-2096.
17. Minard-Colin V, Brugie`res L, Reiter A, et al. Non-Hodgkin lymphoma in children and adolescents: progress through effective collaboration, current
knowledge, and challenges ahead. J Clin Oncol. 2015;33(27):2963-2974.
18. Patte C, Auperin A, Michon J, et al; Socie´te´ Française d’Oncologie Pe´diatrique. The Socie´te´ Française d’Oncologie Pe´diatrique LMB89 protocol: highly
effective multiagent chemotherapy tailored to the tumor burden and initial response in 561 unselected children with B-cell lymphomas and L3 leukemia.
Blood. 2001;97(11):3370-3379.
19. Pillon M, Mussolin L, Carraro E, et al. Detection of prognostic factors in children and adolescents with Burkitt and diffuse large B-cell lymphoma treated
with the AIEOP LNH-97 protocol. Br J Haematol. 2016;175(3):467-475.
20. Reiter A, Schrappe M, Tiemann M, et al. Improved treatment results in childhood B-cell neoplasms with tailored intensification of therapy: a report of the
Berlin-Frankfurt-Mu¨nster Group Trial NHL-BFM 90. Blood. 1999;94(10):3294-3306.
21. Tsurusawa M, Mori T, Kikuchi A, et al; Lymphoma Committee of Japanese Pediatric Leukemia/Lymphoma Study Group. Improved treatment results of
children with B-cell non-Hodgkin lymphoma: a report from the Japanese Pediatric Leukemia/Lymphoma Study Group B-NHL03 study. Pediatr Blood
Cancer. 2014;61(7):1215-1221.
22. Woessmann W, Lisfeld J, Burkhardt B; NHL-BFM Study Group. Therapy in primary mediastinal B-cell lymphoma. N Engl J Med. 2013;369(3):
282-284.
23. WoessmannW, Seidemann K, Mann G, et al; BFMGroup. The impact of the methotrexate administration schedule and dose in the treatment of children
and adolescents with B-cell neoplasms: a report of the BFM Group Study NHL-BFM95. Blood. 2005;105(3):948-958.
24. Harris NL, Jaffe ES, Diebold J, et al. The World Health Organization classification of neoplasms of the hematopoietic and lymphoid tissues: report of the
Clinical Advisory Committee meeting--Airlie House, Virginia, November, 1997. Hematol J. 2000;1(1):53-66.
25. Harris NL, Jaffe ES, Stein H, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study
Group. Blood. 1994;84(5):1361-1392.
26. Stansfeld AG, Diebold J, Noel H, et al. Updated Kiel classification for lymphomas. Lancet. 1988;1(8580):292-293.
27. Campo E, Swerdlow SH, Harris NL, Pileri S, Stein H, Jaffe ES. The 2008WHO classification of lymphoid neoplasms and beyond: evolving concepts and
practical applications. Blood. 2011;117(19):5019-5032.
28. Lansky SB, List MA, Lansky LL, Ritter-Sterr C, Miller DR. The measurement of performance in childhood cancer patients. Cancer. 1987;60(7):
1651-1656.
4296 ATTARBASCHI et al 23 DECEMBER 2019 x VOLUME 3, NUMBER 24
D
ow
nloaded from
 https://ashpublications.org/bloodadvances/article-pdf/3/24/4291/1549805/advancesadv2019001062.pdf by guest on 23 D
ecem
ber 2019
29. Abla O, Weitzman S, Blay JY, et al. Primary CNS lymphoma in children and adolescents: a descriptive analysis from the International Primary CNS
Lymphoma Collaborative Group (IPCG). Clin Cancer Res. 2011;17(2):346-352.
30. O’Suoji C, Welch JJ, Perkins SL, et al. Rare pediatric non-Hodgkin lymphomas: a report from Children’s Oncology Group Study ANHL 04B1. Pediatr
Blood Cancer. 2016;63(5):794-800.
31. Yoon JH, Kang HJ, Kim H, et al. Successful treatment of primary central nervous system lymphoma without irradiation in children: single center
experience. J Korean Med Sci. 2012;27(11):1378-1384.
23 DECEMBER 2019 x VOLUME 3, NUMBER 24 PRIMARY CNS LYMPHOMA IN CHILDREN AND ADOLESCENTS 4297
D
ow
nloaded from
 https://ashpublications.org/bloodadvances/article-pdf/3/24/4291/1549805/advancesadv2019001062.pdf by guest on 23 D
ecem
ber 2019
